Vascular integrin α(v)β3: A new prognostic indicator in breast cancer

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2625-2634

  Gasparini, Giampietro ^a   Brooks, Peter C ^b   Biganzoli, Elia ^e   Vermeulen, Peter B ^c   Bonoldi, Emanuela ^e   Dirix, Luc Y ^c   Ranieri, Girolamo ^a   Miceli, Rosalba ^d   Cheresh, David A ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e National Cancer Institute Milan ^*

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL DIVISION; COHORT STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTEGRINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031724191     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
2. Polverini, P. J. Cellular adhesion molecules. Newly identified mediators of angiogenesis. Am. J. Pathol., 148: 1023-1029, 1996.
3. Hanahan, D., and Folkman J. Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
4. Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69: 11-25, 1992.
5. Strömblad, S., and Cheresh, D. A. Cell adhesion and angiogenesis. Trends Cell Biol., 6: 462-468, 1996.
6. 3 for angiogenesis. Science (Washington DC), 264: 569-571, 1994.
7. v integrins. Science (Washington DC), 270: 1500-1502, 1995.
8. 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell. Sci., 108: 2655-2661, 1995.
9. 3 during angiogenesis. J. Clin. Invest., 98: 426-433, 1996.
10. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest., 96: 1815-1822, 1995.
11. Gasparini, G., Barbareschi, M., Boracchi, P., Verderio, P., Caffo, O., Meli, S., Della Palma, P. D., Marubini, E., and Bevilacqua, P. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J. Sci. Am., 1: 131-141, 1995.
12. Vermeulen, P. B., Verhoeven, D., Hubens, G., Van Marck, E., Goovaerts, G., Huyghe, M., De Bruijn, E. A., Van Oosterom, A. T., and Dirix, L. Y. Microvessel density, endothelial cell proliferation and tumor cell proliferation in human colorectal adenocarcinomas. Ann. Oncol., 6: 59-64, 1995.
13. Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., and Pozza, F. Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol., 12: 454-466, 1994.
14. Vermeulen, P. B., Dirix, L. Y., Libura, J., Vanhoolst, I. F., Van Marck, E., and Van Oosterom, A. T. Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinomas is independent of tumor histotype and microvessel density. Microvasc. Res., 54: 88-92, 1997.
15. Hollander, M., and Wolfe, D. A. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973.
16. Gasparini, G., Toi, M., Gion, M., Verderio, P., Dittadi, R., Hanatani, M., Matsubara, I., Vinante, O., Bonoldi, E., Boracchi, P., Gatti, C., Suzuki, N., and Tominaga, T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. (Bethesda), 89: 139-147, 1997.
17. Harrell, F. E., Lee, K. L., and Mark, D. B. Tutorial in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med., 15: 361-387, 1996.
18. Gasparini, G., and Harris, A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol., 13: 765-782, 1995.
19. Gasparini, G. Current controversies in cancer. Is determination of angiogenic activity in human tumours clinically useful? Eur. J. Cancer, 34: 615-618, 1998.
20. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., McCulloch, P., Pezzella, F., Viale, G., Weidner, N., Harris, A. L., and Dirix, L. Y. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer, 32A: 2474-2484, 1996.
21. Wang, J. M., Kumar, S., Pye, D., Haboubi, N., and Al-Nakib, L. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J. Natl. Cancer Inst. (Bethesda), 86: 386-388, 1994.
22. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. (Bethesda), 84: 1875-1887, 1992.
23. Gasparini, G., Fox, S. B., Verderio, P., Bonoldi, E., Bevilacqua, P., Boracchi, P., Dante, S., Marubini, E., and Harris, A. L. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin. Cancer Res., 2: 1191-1198, 1996.
24. 3. Proc. Am. Soc. Clin. Oncol. 17: 215a, 1998.
25. 3 in the disruption of the tumor vasculature induced by TNF and IFN-γ Nat. Med., 4: 408-414, 1998.
26. Gasparini, G. Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications? Crit. Rev. Oncol. Hematol., 26: 147-162, 1997.